ERNA — ERNEXA THERAPEUTICS INC
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Fundamentals (SEC EDGAR XBRL)
Financials from SEC company facts, point-in-time aligned to each figure’s EDGAR filing date.
| Revenue TTM | Revenue YoY | Net income TTM | Net income YoY | ROE (TTM) | Gross margin | Net margin | P/E (TTM) | P/E pct | P/B | P/B pct |
|---|---|---|---|---|---|---|---|---|---|---|
| $582,000 | -88.1% | -$44.5M | — | -1023.6% | 100.0% | -575900.0% | — | — | — | — |
Net margin trend
Wall Street Analyst Consensus
Ratings, 12-month price target and EPS forecasts from the Nasdaq public analyst feed. · Fetched 2026-11-19
| Fiscal quarter end | Consensus EPS forecast | Forward P/E | High EPS | Low EPS | # estimates | Revisions (4wk up/down) |
|---|---|---|---|---|---|---|
| Dec 2026 | -4.76 | — | -4.76 | -4.76 | 1 | — |
| Fiscal year end | Consensus EPS forecast | Forward P/E | High EPS | Low EPS | # estimates | Revisions (4wk up/down) |
|---|---|---|---|---|---|---|
| Dec 2026 | -18.02 | — | -18.02 | -18.02 | 1 | — |
| Dec 2027 | -1.86 | — | -1.86 | -1.86 | 1 | — |
| Dec 2028 | -1.27 | — | -1.27 | -1.27 | 1 | — |
| Dec 2029 | -1.44 | — | -1.44 | -1.44 | 1 | — |
Forward P/E uses the fetch-time price divided by consensus EPS (quarter annualised ×4). Revision score = (upgrades − downgrades) / estimates, from Nasdaq 4-week counts. Source: Nasdaq analyst data
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
As of Q3 2026, 14 SEC-registered investment managers reported holding ERNA (ERNEXA THERAPEUTICS INC) in their latest 13F filings, with a combined reported value of $173.06K across 54.08K shares. That is -8.6% by share count (-1.75K shares) versus the previous quarter, while reported value moved -56.0%. Ownership is concentrated: the five largest holders account for 96.5% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 6 opened new positions, 1 added to existing stakes, 1 trimmed, 1 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q3 2026, not real-time trading.
Major shareholders of ERNEXA THERAPEUTICS INC (ERNA) include Bleichroeder LP, Citadel Advisors, Corient Private Wealth LP, ranked by reported 13F value among the 49 institutional holders on this page.
ERNA is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 14 | 54.08K | $173.06K | -8.6% |
| Q2 2026 | 9 | 35.52K | $236.24K | -95.0% |
| Q1 2026 | 21 | 3.57M | $711.40K | +51.0% |
| Q4 2025 | 16 | 522.71K | $627.11K | +5.8% |
| Q3 2025 | 16 | 516.94K | $566.05K | +853.4% |
| Q2 2025 | 13 | 49.82K | $91.67K | -92.6% |
| Q1 2025 | 28 | 1.49M | $264.24K | +45.9% |
| Q4 2024 | 26 | 1.02M | $299.39K | +16.8% |
Over the 8 quarters shown, institutional share counts decreased 95% in aggregate (Q4 2024 → Q3 2026); the largest single-quarter swing was Q3 2025 (+853.4%).
Top Institutional Holders (Q3 2026) — 14 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 17.46K | $55.88K | 0.00% | New | |
| 16.08K | $51.45K | 0.00% | New | |
| 8.34K | $26.68K | 0.00% | Hold | |
| 5.68K | $18.19K | 0.00% | Hold | |
| 4.61K | $14.75K | 0.00% | Add | |
| 1.55K | $4.97K | 0.00% | New | |
| 200 | $640 | 0.00% | New | |
| 102 | $326 | 0.00% | New | |
| 33 | $106 | 0.00% | Hold | |
| 19 | $61 | 0.00% | New | |
| 5 | $16 | 0.00% | Hold | |
| 1 | $3 | 0.00% | Hold | |
| 1 | $3 | 0.00% | Hold | |
| 1 | $3 | 0.00% | Reduce |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 9 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 15.10K | $100.44K | 0.00% | Reduce | |
| 8.34K | $55.43K | 0.00% | Reduce | |
| 6.00K | $39.90K | 0.03% | Reduce | |
| 5.68K | $37.80K | 0.00% | Reduce | |
| 361 | $2.40K | 0.00% | New | |
| 33 | $219 | 0.00% | Reduce | |
| 5 | $33 | 0.00% | Reduce | |
| 1 | $7 | 0.00% | Reduce | |
| 1 | $7 | 0.00% | Reduce |
Q1 2026 — 21 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 2.00M | $398.00K | 0.07% | New | |
| 612.44K | $121.88K | 0.08% | New | |
| 438.09K | $87.18K | 0.00% | Hold | |
| 244.45K | $48.64K | 0.00% | Add | |
| 54.34K | $10.81K | 0.00% | New | |
| 50.00K | $10.05K | 0.01% | New | |
| 41.17K | $8.19K | 0.00% | New | |
| 33.08K | $6.58K | 0.00% | New | |
| 26.50K | $5.27K | 0.00% | New | |
| 25.45K | $5.06K | 0.00% | New | |
| 21.23K | $4.22K | 0.00% | Add | |
| 16.63K | $3.31K | 0.00% | New | |
| 10.00K | $1.99K | 0.00% | Hold | |
| 820 | $163 | 0.00% | Hold | |
| 133 | $26 | 0.00% | Hold | |
| 10 | $2 | 0.00% | Hold | |
| 8 | $2 | 0.00% | Hold | |
| 8 | $2 | 0.00% | Hold | |
| 8 | $2 | 0.00% | Hold | |
| 3 | $1 | 0.00% | Hold | |
| 6 | $1 | 0.00% | New |
Q4 2025 — 16 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 438.09K | $525.71K | 0.00% | Hold | |
| 35.92K | $43.11K | 0.00% | Add | |
| 23.62K | $28.34K | 0.00% | Add | |
| 12.62K | $15.00K | 0.00% | New | |
| 10.00K | $12.00K | 0.01% | Hold | |
| 820 | $984 | 0.00% | Hold | |
| 804 | $965 | 0.00% | New | |
| 600 | $720 | 0.00% | New | |
| 133 | $160 | 0.00% | Hold | |
| 34 | $41 | 0.00% | Add | |
| 30 | $36 | 0.00% | Reduce | |
| 10 | $12 | 0.00% | Hold | |
| 8 | $10 | 0.00% | Hold | |
| 8 | $10 | 0.00% | Hold | |
| 8 | $10 | 0.00% | Hold | |
| 3 | $4 | 0.00% | Hold |
Q3 2025 — 16 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 438.09K | $479.71K | 0.00% | Add | |
| 30.85K | $33.78K | 0.00% | New | |
| 20.45K | $22.40K | 0.00% | Add | |
| 11.15K | $12.21K | 0.00% | New | |
| 10.00K | $10.95K | 0.01% | Hold | |
| 5.18K | $5.67K | 0.00% | New | |
| 820 | $898 | 0.00% | Hold | |
| 133 | $146 | 0.00% | Hold | |
| 116 | $127 | 0.00% | Hold | |
| 77 | $84 | 0.00% | Reduce | |
| 33 | $36 | 0.00% | Add | |
| 10 | $11 | 0.00% | Hold | |
| 8 | $9 | 0.00% | Hold | |
| 8 | $9 | 0.00% | Hold | |
| 8 | $9 | 0.00% | New | |
| 3 | $3 | 0.00% | Hold |
Q2 2025 — 13 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 20.07K | $36.94K | 0.00% | Reduce | |
| 17.52K | $32.24K | 0.00% | Reduce | |
| 10.00K | $18.40K | 0.01% | Reduce | |
| 820 | $1.51K | 0.00% | Reduce | |
| 554 | $1.02K | 0.00% | New | |
| 548 | $1.01K | 0.00% | Reduce | |
| 133 | $245 | 0.00% | Reduce | |
| 116 | $213 | 0.00% | Reduce | |
| 21 | $39 | 0.00% | Reduce | |
| 10 | $18 | 0.00% | Reduce | |
| 8 | $15 | 0.00% | Reduce | |
| 8 | $15 | 0.00% | Reduce | |
| 3 | $6 | 0.00% | Reduce |
New Positions (Q3 2026)
- Corient Private Wealth LP 17.46K sh · $55.88K
- Geode Capital Management 16.08K sh · $51.45K
- Tower Research Capital LLC (TRC) 1.55K sh · $4.97K
- Morgan Stanley 200 sh · $640
- Citigroup Inc 102 sh · $326
- UBS Group AG 19 sh · $61
Fully Exited (vs previous quarter)
- Citadel Advisors sold 15.10K sh · $100.44K
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corient Private Wealth LP | 17.46K | — | 438.09K | 438.09K | 438.09K | 17.52K | 262.86K | 262.86K | 262.86K | 50.40K | 50.40K | 50.40K | 51.31K | — | — | — |
| Geode Capital Management | 16.08K | — | 244.45K | 23.62K | 20.45K | 20.07K | 293.15K | 257.31K | 20.43K | 23.72K | 22.49K | 22.49K | 22.49K | 13.69K | 13.98K | 13.98K |
| VANGUARD FIDUCIARY TRUST CO | 8.34K | 8.34K | 25.45K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.68K | 5.68K | 26.50K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Tradewinds Capital Management, LLC | 4.61K | 361 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Tower Research Capital LLC (TRC) | 1.55K | — | — | — | 5.18K | — | — | — | 4.99K | 5.17K | 4.08K | 4.41K | 4.60K | — | — | — |
| Morgan Stanley | 200 | — | — | 30 | 77 | 554 | — | — | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 1.36K |
| Citigroup Inc | 102 | — | — | — | — | — | 153.16K | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| BlackRock Inc | 33 | 33 | 820 | 820 | 820 | 820 | 12.30K | 14.92K | 14.92K | — | — | — | — | — | — | — |
| UBS Group AG | 19 | — | 21.23K | 600 | — | 548 | 12.47K | 16.86K | 83.62K | — | 741 | — | 105 | — | 3.86K | — |
| ASSETMARK, INC | 5 | 5 | 133 | 133 | 133 | 133 | 2.00K | — | — | — | — | — | — | — | — | — |
| Dauntless Investment Group, LLC | 1 | 6.00K | 612.44K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| BNP PARIBAS FINANCIAL MARKETS | 1 | 1 | 10 | 10 | 10 | 10 | 140 | 140 | — | — | — | — | — | — | — | — |
| SBI Securities Co., Ltd. | 1 | 1 | 6 | — | — | — | 10 | 10 | — | — | — | — | — | — | — | — |
| Bleichroeder LP | — | — | 2.00M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cypress Point Wealth Management, LLC | — | — | — | — | — | — | 94.38K | 94.38K | 94.38K | 94.38K | 94.38K | 94.38K | 94.38K | — | — | — |
| Naviter Wealth, LLC | — | — | — | — | — | — | 47.27K | 47.27K | 78.80K | 78.80K | 78.80K | 78.80K | 79.30K | — | — | — |
| Sippican Capital Advisors | — | — | 10.00K | 10.00K | 10.00K | 10.00K | 80.00K | 50.00K | 68.50K | 72.80K | 72.80K | 54.05K | 28.10K | — | — | — |
| Citadel Advisors | — | 15.10K | 33.08K | — | — | — | 65.57K | — | — | — | 10.09K | — | — | — | — | — |
| Vanguard Group | — | — | — | 35.92K | 11.15K | — | 38.19K | 26.10K | 26.10K | 26.10K | 26.10K | 26.10K | 24.90K | 19.07K | 19.07K | 29.07K |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold ERNA?
As of 2026-Q3, 14 institutional funds reported holding ERNA (ERNEXA THERAPEUTICS INC) in SEC 13F filings, with a combined reported value of $173.06K.
How many shares of ERNA do institutions own?
13F filers reported 54.08K shares of ERNA, worth $173.06K in aggregate at the end of 2026-Q3.
Is institutional ownership of ERNA rising or falling?
Share counts moved -8.6% versus the prior quarter — distribution.
Who are the top institutional holders of ERNA?
The largest 13F holders are Bleichroeder LP, Citadel Advisors, Corient Private Wealth LP, Geode Capital Management, Vanguard Group; the top 25 are ranked at the top of this page.
Who are the major shareholders of ERNEXA THERAPEUTICS INC?
The major shareholders of ERNEXA THERAPEUTICS INC (ERNA) by reported 13F value are Bleichroeder LP, Citadel Advisors, Corient Private Wealth LP, Geode Capital Management, Vanguard Group, among 49 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.